COOPERATIVE PATENT CLASSIFICATION
PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-
up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing
beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link
than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic
peptide type C07D 519/02; macromolecular compounds having statistically distributed amino
acid units in their molecules, i.e. when the preparation does not provide for a specific; but for
a random sequence of the amino acid units, homopolyamides and block copolyamides derived
from amino acids C08G 69/00; macromolecular products derived from proteins C08H 1/00;
preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering
processes for obtaining peptides C12N 15/00; compositions for measuring or testing processes
involving enzymes C12Q; investigation or analysis of biological material G01N 33/00)
1. In this subclass, the following terms or expressions are used with the meanings indicated:
• "amino acids" are compounds in which at least one amino group and at least one carboxyl group are bound to the same
carbon skeleton and the nitrogen atom of the amino group may form part of a ring;
• "normal peptide link" is one between an alpha-amino group of an amino acid and the carboxyl group - in position 1 - of
• "abnormal peptide link" is a link where at least one of the linked amino acids is not an alpha-amino acid or a link formed
by at least one carboxyl or amino group being part of the side chain of a alpha-amino acid;
• "peptides" are compounds containing at least two amino acid units, which are bound through at least one normal peptide
link, including oligopeptides, polypeptides and proteins, where:
i. "linear peptides" may comprise rings formed through S-S bridges, or through a hydroxy or a mercapto group of an
hydroxy- or mercapto-amino acid and the carboxyl group of another amino acid, (e.g. peptide lactones) but do not
comprise rings which are formed only through peptide links;
ii. "cyclic peptides" are peptides comprising at least one ring formed only through peptide links; the cyclisation may occur
only through normal peptide links or through abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-
butanoic acid. Thus, cyclic compounds in which at least one link in the ring is a non-peptide link are considered as
iii. "depsipeptides" are compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy
carboxylic acid, which are bound through at least one normal peptide link and ester links, derived from the hydroxy
a. "linear depsipeptides" may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group
of an hydroxy- or mercapto-amino acid and the carboxyl group of another amino- of hydroxy-acid but do not
comprise rings formed only through peptide or ester links derived from hydroxy carboxylic acids, e.g. Gly-Ala-Gly-
OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as "linear depsipeptides", but HOCH2CO-Gly-Ala-Gly does
not contain an ester link, and is thus a derivative of Gly-Ala-Gly which is covered by  C07K 5/08;
b. "cyclic depsipeptides" are peptides containing at least one ring formed only through peptide or ester links - derived
from hydroxy carboxylic acids -, e.g. Gly-Ala-Gly-OCH2CO.
2. Fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others,
or by combination of these modifications, are classified as the parent peptides. However, fragments of peptides having only
four or less amino acids are also classified in group C07K 5/00.
3. Peptides prepared by chemical processes and having an amino acid sequence derived from naturally occurring peptides are
classified with the natural one.
4. Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original
peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.
5. When classifying in this subclass, classification is also made in group B01D 15/08 insofar as subject matter of general interest
relating to chromatography is concerned.
1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following
2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the
    1/00    General methods for the preparation of peptides {,
i.e. processes for the organic chemical preparation
of peptides or proteins of any length}
    1/003   . {by transforming the C-terminal amino acid to
    1/006   . {of peptides containing derivatised side chain amino
    1/02    . in solution {(C07K 1/003, C07K 1/006 take
    1/023   . . {using racemisation inhibiting agents}
    1/026   . . {by fragment condensation in solution}
    1/04    . on carriers {(C07K 1/003, C07K 1/006 take
    1/042   . . {characterised by the nature of the carrier}
    1/045   . . {using devices to improve synthesis, e.g. reactors,
    1/047   . . {Simultaneous synthesis of different peptide
    1/06    . using protecting groups or activating agents
{(C07K 1/003, C07K 1/006 take precedence)}
    1/061   . . {using protecting groups}
    1/062   . . . {for alpha- or omega-carboxy functions}
    1/063   . . . {for alpha-amino functions}
    1/064   . . . {for omega-amino or -guanidino functions}
    1/065   . . . {for hydroxy functions, not being part of
    1/066   . . . {for omega-amido functions}
    1/067   . . . {for sulfur-containing functions}
    1/068   . . . {for heterocyclic side chains}
    1/08    . . using activating agents {(C07K 1/003,
    1/082   . . . {containing phosphorus}
    1/084   . . . {containing nitrogen}
    1/086   . . . {containing sulfur}
    1/088   . . . {containing other elements, e.g. B, Si, As}
    1/10    . using coupling agents {(C07K 1/006 takes
    1/107   . by chemical modification of precursor peptides
    1/1072  . . {by covalent attachment of residues or functional
    1/1075  . . . {by covalent attachment of amino acids or
    1/1077  . . . {by covalent attachment of residues other than
amino acids or peptide residues, e.g. sugars,
    1/113   . . without change of the primary structure
    1/1133  . . . {by redox-reactions involving cystein/cystin
    1/1136  . . . {by reversible modification of the secondary,
tertiary or quarternary structure, e.g. using
denaturating or stabilising agents}
    1/12    . by hydrolysis {, i.e. solvolysis in general}
    1/122   . . {Hydrolysis with acids different from HF}
    1/124   . . {Hydrazinolysis}
    1/13    . Labelling of peptides
    1/14    . Extraction; Separation; Purification
    1/145   . . {by extraction or solubilisation}
    1/16    . . by chromatography
    1/165   . . . {mixed-mode chromatography}
    1/18    . . . Ion-exchange chromatography
    1/20    . . . Partition-, reverse-phase or hydrophobic
    1/22    . . . Affinity chromatography or related techniques
based upon selective absorption processes
    1/24    . . by electrochemical means
    1/26    . . . Electrophoresis
    1/28    . . . . Isoelectric focusing
    1/285   . . . . . {multi dimensional electrophoresis}
    1/30    . . by precipitation
    1/303   . . . {by salting out}
    1/306   . . . {by crystallization}
Large single crystals of proteins from
solutions are classified in C30B 7/00 for the
method and in C30B 29/58 for the crystal
    1/34    . . by filtration, ultrafiltration or reverse osmosis
    1/36    . . by a combination of two or more processes of
    2/00    Peptides of undefined number of amino acids;
    4/00    Peptides having up to 20 amino acids in an
undefined or only partially defined sequence;
    4/08    . from algae; from lichens
    4/12    . from animals; from humans
If no indication to the contrary is given, all
amino acids are considered to be in the natural L-
    5/00    Peptides containing up to four amino acids in a
fully defined sequence; Derivatives thereof
    5/02    . containing at least one abnormal peptide link
    5/0202  . . {containing the structure -NH-X-X-C(=0)-, X
being an optionally substituted carbon atom or a
heteroatom, e.g. beta-amino acids}
    5/0205  . . {containing the structure -NH-(X)3-C(=0)-, e.g.
statine or derivatives thereof}
    5/0207  . . {containing the structure -NH-(X)4-C(=0), e.g.
'isosters', replacing two amino acids}
    5/021   . . {containing the structure -NH-(X)n-C(=0)-,
n being 5 or 6; for n > 6, classification in
C07K 5/06 - C07K 5/10, according to the moiety
    5/0212  . . {containing the structure -N-C-N-C(=0)-, e.g.
    5/0215  . . {containing natural amino acids, forming a
peptide bond via their side chain functional
group, e.g. epsilon-Lys, gamma-Glu}
    5/0217  . . {containing the structure -C(=O)-C-N-C(=O)-N-
    5/022   . . {containing the structure -X-C(=O)-(C)n-N-C-
C(=O)-Y-; X and Y being heteroatoms; n being 1
    5/0222  . . . {with the first amino acid being heterocyclic,
    5/0225  . . {containing the structure -N-C-C(=O)-N-C(=O)-
    5/0227  . . {containing the (partial) peptide sequence -Phe-
His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n
= 2 - 6; for n > 6 see C07K 5/06 - C07K 5/10}
    5/04    . containing only normal peptide links
In groups C07K 5/06 - C07K 5/10 the following
terms or expressions are used with the meaning
amino groups than carboxylic acid
having only acyclic carbon atoms
having a carbocyclic ring in the
or is part of a heteroring, e.g.
in the optionally functionalised
    5/06008 . . . {with the first amino acid being neutral}
    5/06017 . . . . {and aliphatic}
    5/06026 . . . . . {the side chain containing 0 or 1 carbon
    5/06034 . . . . . {the side chain containing 2 to 4 carbon
    5/06043 . . . . . . {Leu-amino acid}
    5/06052 . . . . . . {Val-amino acid}
    5/0606  . . . . . {the side chain containing
heteroatoms not provided for by
C07K 5/06086 - C07K 5/06139, e.g. Ser,
    5/06069 . . . . . . {Ser-amino acid}
    5/06078 . . . . {and aromatic or cycloaliphatic}
    5/06086 . . . {with the first amino acid being basic}
    5/06095 . . . . {Arg-amino acid}
    5/06104 . . . {with the first amino acid being acidic}
    5/06113 . . . . {Asp- or Asn-amino acid}
    5/06121 . . . . . {the second amino acid being aromatic or
    5/0613  . . . . . . {Aspartame}
    5/06139 . . . {with the first amino acid being heterocyclic}
    5/06147 . . . . {and His-amino acid; Derivatives thereof}
    5/06156 . . . . {and Trp-amino acid; Derivatives thereof}
    5/06165 . . . . {and Pro-amino acid; Derivatives thereof}
    5/06173 . . . . {and Glp-amino acid; Derivatives thereof}
    5/06182 . . . . {and Pristinamycin II; Derivatives thereof}
    5/06191 . . . {containing heteroatoms different from O, S, or
    5/0802  . . . {with the first amino acid being neutral}
    5/0804  . . . . {and aliphatic}
    5/0806  . . . . . {the side chain containing 0 or 1 carbon
    5/0808  . . . . . {the side chain containing 2 to 4 carbon
    5/081   . . . . . {the side chain containing O or S as
    5/0812  . . . . {and aromatic or cycloaliphatic}
    5/0815  . . . {with the first amino acid being basic}
    5/0817  . . . . {the first amino acid being Arg}
    5/0819  . . . {with the first amino acid being acidic}
    5/0821  . . . {with the first amino acid being heterocyclic,
    5/0823  . . . . {and Pro-amino acid; Derivatives thereof}
    5/0825  . . . . {and Glp-amino acid; Derivatives thereof}
    5/0827  . . . {containing heteroatoms different from O, S, or
    5/1002  . . . {with the first amino acid being neutral}
    5/1005  . . . . {and aliphatic}
    5/1008  . . . . . {the side chain containing 0 or 1 carbon
    5/101   . . . . . {the side chain containing 2 to 4 carbon
    5/1013  . . . . . {the side chain containing O or S as
    5/1016  . . . . {and aromatic or cycloaliphatic}
    5/1019  . . . {with the first amino acid being basic}
    5/1021  . . . {with the first amino acid being acidic}
    5/1024  . . . {with the first amino acid being heterocyclic}
    5/1027  . . . {containing heteroatoms different from O, S, or
    5/12    . . Cyclic peptides {with only normal peptide bonds
Cyclic peptides containing at least one
abnormal peptide link are classified as linear
    5/123   . . . {Tripeptides}
    5/126   . . . {Tetrapeptides}
    7/00    Peptides having 5 to 20 amino acids in a fully
defined sequence; Derivatives thereof
In this subgroup cyclic compounds related to
specific compounds which are classified in a
specific group, e.g. C07K 7/062, are classified in
    7/02    . Linear peptides containing at least one abnormal
    7/04    . Linear peptides containing only normal peptide
    7/06    . . having 5 to 11 amino acids
    7/062   . . . {Serum thymic factor}
    7/065   . . . {Thymic humoral factor}
    7/067   . . . {Hemoregulatory peptides based on sequence
    7/08    . . having 12 to 20 amino acids (gastrins
C07K 14/595; somatostatins C07K 14/655;
    7/083   . . . {Neurotensin}
    7/086   . . . {Bombesin; Related peptides (having more
than 20 amino acids C07K 14/57572)}
    7/14    . . Angiotensins: Related peptides
    7/16    . . Oxytocins; Vasopressins; Related peptides
    7/18    . . Kallidins; Bradykinins; Related peptides
    7/22    . . {Tachykinins, e.g.} Eledoisins {, Substance P};
    7/23    . . Luteinising hormone-releasing hormone [LHRH];
    7/28    . . Gramicidins A, B, D; Related peptides
    7/50    . Cyclic peptides containing at least one abnormal
    7/52    . . with only normal peptide links in the ring
    7/54    . . with at least one abnormal peptide link in the ring
    7/56    . . . the cyclisation not occurring through 2,4-
    7/58    . . . . Bacitracins; Related peptides
    7/60    . . . the cyclisation occurring through the 4-amino
group of 2,4-diamino-butanoic acid
    7/62    . . . . Polymyxins; Related peptides
    7/64    . Cyclic peptides containing only normal peptide
    7/645   . . {Cyclosporins; Related peptides}
    7/66    . . Gramicidins S, C; Tyrocidins A, B, C; Related
    9/00    Peptides having up to 20 amino acids, containing
saccharide radicals and having a fully defined
    9/001   . {the peptide sequence having less than 12 amino
acids and not being part of a ring structure}
    9/003   . . {Peptides being substituted by heterocyclic
radicals, e.g. bleomycin, phleomycin}
    9/005   . . {containing within the molecule the substructure
0 and m+n > 0, A, B, D, E being heteroatoms; X
being a bond or a chain, e.g. muramylpeptides}
    9/006   . {the peptide sequence being part of a ring structure}
    9/008   . . {directly attached to a hetero atom of the
saccharide radical, e.g. actaplanin, avoparcin,
   11/00    Depsipeptides having up to 20 amino acids in a
fully defined sequence; Derivatives thereof
   11/02    . cyclic, e.g. valinomycins {Derivatives thereof}
   14/00    Peptides having more than 20 amino acids;
Gastrins; Somatostatins; Melanotropins;
   14/001   . {by chemical synthesis}
   14/003   . . {Peptide-nucleic acids (PNAs)}
When classifying in this group, subject-matter
related to viral proteins shall be classified by
the symbol C07K 14/005 together with (a
number of) appropriate indexing codes out of
C07K 14/01 - C07K 14/19 and subgroups thereof
are no longer used for the classification of new
documents. 2. Reclassification of the back-file
follows the principle outlined in the Note here
   14/015   . . . Parvoviridae, e.g. feline panleukopenia virus,
   14/02    . . . Hepadnaviridae, e.g. hepatitis B virus
   14/025   . . . Papovaviridae, e.g. papillomavirus,
polyomavirus, SV40, BK virus, JC virus
   14/03    . . . Herpetoviridae, e.g. pseudorabies virus
   14/032   . . . . {Pseudorabies virus, i.e. Anjetzky virus}
   14/035   . . . . Herpes simplex virus I or II
   14/04    . . . . Varicella-zoster virus
   14/045   . . . . . Cytomegalovirus
   14/05    . . . . Epstein-Barr virus
   14/055   . . . . Marek's disease virus
   14/06    . . . . Infectious bovine rhinotracheitis virus
   14/065   . . . Poxviridae, e.g. avipoxvirus
   14/07    . . . . Vaccinia virus; Variola virus
   14/082   . . . {Arteriviridae, e.g. EAV, PRRSV}
   14/085   . . . Picornaviridae, e.g. coxsackie virus, echovirus,
   14/09    . . . . Foot-and-mouth disease virus
   14/10    . . . . Hepatitis A virus
   14/11    . . . Orthomyxoviridae, e.g. influenza virus
   14/115   . . . Paramyxoviridae, e.g. parainfluenza virus
   14/12    . . . . Mumps virus; Measles virus
   14/125   . . . . Newcastle disease virus
   14/13    . . . . Canine distemper virus
   14/135   . . . . Respiratory syncytial virus
   14/14    . . . Reoviridae, e.g. rotavirus, bluetongue virus,
   14/145   . . . Rhabdoviridae, e.g. rabies virus, Duvenhage
virus, Mokola virus or vesicular stomatitis virus
   14/15    . . . Retroviridae, e.g. bovine leukaemia virus,
feline leukaemia virus human T-cell leukaemia-
   14/155   . . . . Lentiviridae, e.g. visna-maedi virus, equine
   14/16    . . . . . HIV-1 {; HIV-2}
   14/161   . . . . . . {gag-pol, e.g. p55, p24/25, p17/18, p7,
p6, p66/68, p51/52, p31/34, p32, p40}
   14/162   . . . . . . {env, e.g. gp160, gp110/120, gp41, V3,
   14/163   . . . . . . {Regulatory proteins, e.g. tat, nef, rev,
   14/165   . . . Coronaviridae, e.g. avian infectious bronchitis
   14/17    . . . . Porcine transmissible gastroenteritis virus
   14/175   . . . Bunyaviridae, e.g. California encephalitis virus,
Rift valley fever virus, Hantaan virus
   14/18    . . . Togaviridae; {Flaviviridae}
   14/1808  . . . . {Alphaviruses or Group A arboviruses, e.g.
sindbis, VEE, EEE, WEE, semliki forest
virus (rubella virus C07K 14/19)}
   14/1816  . . . . {Flaviviridae, e.g. pestivirus, mucosal
disease virus, bovine viral diarrhoea virus,
classical swine fever virus (hog cholera
   14/1825  . . . . . {Flaviviruses or Group B arboviruses, e.g.
yellow fever virus, japanese encephalitis,
tick-borne encephalitis, dengue}
   14/1833  . . . . . {Hepatitis C; Hepatitis NANB}
   14/1841  . . . . . {Hepatitis G; Hepatitis NANBNCNDNE}
   14/19    . . . . Rubella virus
In groups C07K 14/20 - C07K 14/365, where
appropriate, after the bacteria terminology, the
indication of the order (O), family (F) or genus
(G) of the bacteria is given in brackets.
   14/20    . . from Spirochaetales (O), e.g. Treponema,
   14/205   . . from Campylobacter (G)
   14/21    . . from Pseudomonadaceae (F)
   14/212   . . . {Moraxellaceae, e.g. Acinetobacter, Moraxella,
   14/215   . . from Halobacteriaceae (F)
   14/22    . . from Neisseriaceae (F)
   14/225   . . from Alcaligenes (G)
   14/23    . . from Brucella (G)
   14/235   . . from Bordetella (G)
   14/24    . . from Enterobacteriaceae (F), e.g. Citrobacter,
Serratia, Proteus, Providencia, Morganella,
   14/245   . . . Escherichia (G)
   14/255   . . . Salmonella (G)
   14/26    . . . Klebsiella (G)
   14/265   . . . Enterobacter (G)
   14/28    . . from Vibrionaceae (F)
   14/285   . . from Pasteurellaceae (F), e.g. Haemophilus
   14/29    . . from Richettsiales (O)
   14/295   . . from Chlamydiales (O)
   14/30    . . from Mycoplasmatales, e.g. Pleuropneumonia-
   14/305   . . from Micrococcaceae (F)
   14/31    . . . from Staphylococcus (G)
   14/315   . . from Streptococcus (G), e.g. Enterococci
   14/3153  . . . {Streptokinase}
   14/3156  . . . {from Streptococcus pneumoniae
   14/32    . . from Bacillus (G)
   14/325   . . . Bacillus thuringiensis crystal protein (delta-
   14/33    . . from Clostridium (G)
   14/335   . . from Lactobacillus (G)
   14/34    . . from Corynebacterium (G)
   14/345   . . from Brevibacterium (G)
   14/35    . . from Mycobacteriaceae (F)
   14/355   . . from Nocardia (G)
   14/36    . . from Actinomyces; from Streptomyces (G)
   14/365   . . from Actinoplanes (G)
   14/375   . . from Basidiomycetes
   14/38    . . from Aspergillus
   14/385   . . from Penicillium
   14/395   . . . from Saccharomyces
   14/42    . . Lectins, e.g. concanavalin, phytohaemagglutinin
   14/43    . . {Sweetening agents, e.g.} thaumatin, {monellin}
   14/435   . from animals; from humans
   14/43504 . . {from invertebrates}
   14/43509 . . . {from crustaceans}
   14/43513 . . . {from arachnidae}
   14/43518 . . . . {from spiders}
   14/43522 . . . . {from scorpions}
   14/43527 . . . . {from ticks}
   14/43531 . . . . {from mites}
   14/4354  . . . . {from nematodes}
   14/43545 . . . . . {from Caenorhabditis}
   14/4355  . . . . {from cestodes}
   14/43554 . . . . . {from Taenia}
   14/43559 . . . . {from trematodes}
   14/43563 . . . {from insects}
   14/43568 . . . . {from wasps}
   14/43572 . . . . {from bees}
   14/43577 . . . . {from flies}
   14/43581 . . . . . {from Drosophila}
   14/43586 . . . . {from silkworms}
   14/4359  . . . . {from fleas}
   14/43595 . . . {from coelenteratae, e.g. medusae}
   14/46    . . from vertebrates
   14/463   . . . {from amphibians}
   14/4702  . . . . . {Regulators; Modulating activity}
   14/4703  . . . . . . {Inhibitors; Suppressors}
   14/4705  . . . . . . {stimulating, promoting or activating
   14/4706  . . . . . . . {Guanosine triphosphatase activating
   14/4707  . . . . . {Muscular dystrophy}
   14/4708  . . . . . . {Duchenne dystrophy}
   14/471   . . . . . . {Myotonic dystrophy}
   14/4711  . . . . . {Alzheimer's disease; Amyloid plaque
   14/4712  . . . . . {Cystic fibrosis}
   14/4713  . . . . . {Autoimmune diseases, e.g. Insulin-
dependent diabetes mellitus, multiple
sclerosis, rheumathoid arthritis, systemic
lupus erythematosus; Autoantigens}
   14/4715  . . . . . {Pregnancy proteins, e.g. placenta
proteins, alpha-feto-protein, pregnancy
   14/4716  . . . . . {Muscle proteins, e.g. myosin, actin}
   14/4717  . . . . . {Plasma globulins, lactoglobulin}
   14/4718  . . . . . {Cytokine-induced proteins}
   14/472   . . . . . {Complement proteins, e.g. anaphylatoxin,
   14/4721  . . . . . {Lipocortins}
   14/4722  . . . . . {G-proteins}
   14/4723  . . . . . {Cationic antimicrobial peptides, e.g.
   14/4725  . . . . . {Proteoglycans, e.g. aggreccan}
   14/4726  . . . . . {Lectins}
   14/4727  . . . . . {Mucins, e.g. human intestinal mucin}
   14/4728  . . . . . {Calcium binding proteins, e.g.
   14/473   . . . . . {alpha-Glycoproteins}
   14/4731  . . . . . {Recognins, e.g. malignin}
   14/4732  . . . . . {Casein (in foodstuffs A23J)}
   14/4733  . . . . . {Acute pancreatitis-associated protein}
   14/4736  . . . . . {Retinoblastoma protein}
   14/4737  . . . . . {C-reactive protein}
   14/4738  . . . . . {Cell cycle regulated proteins, e.g. cyclin,
CDC, INK-CCR (cell cycle dependent
   14/474   . . . . . {Pancreatic thread protein; Reg protein}
   14/4741  . . . . . {Keratin; Cytokeratin}
   14/4742  . . . . . {Bactericidal/Permeability-increasing
   14/4743  . . . . . {Insulin-like growth factor binding
   14/4745  . . . . . {Cancer-associated SCM-recognition
   14/4747  . . . . . {Apoptosis related proteins}
   14/4748  . . . . . {Tumour specific antigens; Tumour
rejection antigen precursors [TRAP], e.g.
   14/475   . . Growth factors; Growth regulators
   14/4753  . . . {Hepatocyte growth factor; Scatter factor;
   14/4756  . . . {Neuregulins, i.e. p185erbB2 ligands,
glial growth factor, heregulin, ARIA, neu
   14/48    . . . Nerve growth factor [NGF]
   14/485   . . . Epidermal growth factor [EGF] (urogastrone)
   14/49    . . . Platelet-derived growth factor [PDGF]
   14/495   . . . Transforming growth factor [TGF]
   14/50    . . . Fibroblast growth factors [FGF]
   14/501   . . . . {acidic FGF [aFGF]}
   14/503   . . . . {basic FGF [bFGF]}
   14/505   . . . Erythropoietin [EPO]
   14/51    . . . Bone morphogenetic factor; Osteogenins;
Osteogenic factor; Bone-inducing factor
   14/515   . . . Angiogenesic factors; Angiogenin
   14/52    . . Cytokines; Lymphokines; Interferons
   14/522   . . . . {Alpha-chemokines, e.g. NAP-2, ENA-78,
GRO-alpha/MGSA/NAP-3, GRO-beta/
MIP-2alpha, GRO-gamma/MIP-2beta, IP-10,
   14/523   . . . . {Beta-chemokines, e.g. RANTES, I-309/
TCA-3, MIP-1alpha, MIP-1beta/ACT-2/
   14/524   . . . {Thrombopoietin, i.e. C-MPL ligand}
   14/525   . . . Tumour necrosis factor [TNF]
   14/5255  . . . . {Lymphotoxin [LT]}
   14/53    . . . Colony-stimulating factor [CSF]
   14/535   . . . . Granulocyte CSF; Granulocyte-macrophage
   14/54    . . . Interleukins [IL]
   14/5415  . . . . {Leukaemia inhibitory factor [LIF]}
   14/555   . . . Interferons [IFN]
   14/575   . . Hormones (derived from pro-opiomelanocortin,
pro-enkephalin or pro-dynorphin C07K 14/665,
e.g. corticotropin C07K 14/695)
   14/57509 . . . {Corticotropin releasing factor [CRF]
   14/57518 . . . {Placental lactogen; Chorionic
   14/57527 . . . {Calcitonin gene related peptide}
   14/57536 . . . {Endothelin, vasoactive intestinal contractor
   14/57545 . . . {Neuropeptide Y}
   14/57563 . . . {Vasoactive intestinal peptide [VIP]; Related
   14/57572 . . . {Gastrin releasing peptide (bombesin
   14/57581 . . . {Thymosin; Related peptides}
   14/5759  . . . {Products of obesity genes, e.g. leptin, obese
   14/58    . . . Atrial natriuretic factor complex; Atriopeptin;
Atrial natriuretic peptide [ANP]; Cardionatrin;
   14/582   . . . . {at least 1 amino acid in D-form}
   14/5855  . . . . {at least 1 amino acid in D-form}
   14/59    . . . Follicle-stimulating hormone [FSH]; Chorionic
gonadotropins, e.g. HCG; Luteinising hormone
[LH]; Thyroid-stimulating hormone [TSH]
   14/592   . . . . {at least 1 amino acid in D-form}
   14/595   . . . Gastrins; Cholecystokinins [CCK]
   14/5955  . . . . {at least 1 amino acid in D-form}
   14/60    . . . Growth-hormone releasing factors (GH-RF)
   14/61    . . . Growth hormones [GH] (Somatotropin)
   14/615   . . . . Extraction from natural sources
   14/622   . . . . {at least 1 amino acid in D-form}
   14/625   . . . . Extraction from natural sources
   14/635   . . . Parathyroid hormone (parathormone);
Parathyroid hormone-related peptides
   14/65    . . . Insulin-like growth factors (Somatomedins),
   14/655   . . . Somatostatins
   14/6555  . . . . {at least 1 amino acid in D-form}
   14/66    . . . Thymopoietins
   14/662   . . . . {at least 1 amino acid in D-form}
   14/665   . . derived from pro-opiomelanocortin, pro-
   14/67    . . . Lipotropins, e.g. beta, gamma lipotropin
   14/672   . . . . {with at least 1 amino acid in D-form}
   14/675   . . . Beta-endorphins
   14/6755  . . . . {with at least 1 amino acid in D-form}
   14/68    . . . Melanocyte-stimulating hormone [MSH]
   14/685   . . . . Alpha-melanotropin
   14/69    . . . . Beta-melanotropin
   14/695   . . . Corticotropin [ACTH]
   14/6955  . . . . {with at least 1 amino acid in D-form}
   14/702   . . . . {with at least 1 amino acid in D-form}
   14/705   . . Receptors; Cell surface antigens; Cell surface
determinants {(tumour specific antigens
   14/70503 . . . {Immunoglobulin superfamily}
   14/7051  . . . . {T-cell receptor (TcR)-CD3 complex}
   14/70521 . . . . {CD28, CD152}
   14/70525 . . . . {ICAM molecules, e.g. CD50, CD54,
   14/70532 . . . . {B7 molecules, e.g. CD80, CD86}
   14/70535 . . . . {Fc-receptors, e.g. CD16, CD32, CD64
   14/70539 . . . . {MHC-molecules, e.g. HLA-molecules}
   14/70546 . . . {Integrin superfamily}
   14/7055  . . . . {Integrin beta1-subunit-containing
   14/70553 . . . . {Integrin beta2-subunit-containing
   14/70557 . . . . {Integrin beta3-subunit-containing
molecules, e.g. CD41, CD51, CD61}
   14/7056  . . . {Lectin superfamily, e.g. CD23, CD72}
   14/70564 . . . . {Selectins, e.g. CD62}
   14/70567 . . . {Nuclear receptors, e.g. retinoic acid receptor
[RAR], RXR, nuclear orphan receptors}
   14/70571 . . . {for neuromediators, e.g. serotonin receptor,
   14/70575 . . . {NGF/TNF-superfamily, e.g. CD70, CD95L,
CD153, CD154 (NGF C07K 14/48, TNF
   14/70578 . . . {NGF-receptor/TNF-receptor superfamily, e.g.
CD27, CD30, CD40, CD95 (NGF-receptor
C07K 14/71, TNF-receptor C07K 14/7151)}
   14/70596 . . . {Molecules with a "CD"-designation not
   14/71    . . . for growth factors; for growth regulators
   14/715   . . . for cytokines; for lymphokines; for interferons
   14/7151  . . . . {for tumor necrosis factor [TNF], for
   14/7153  . . . . {for colony-stimulating factors [CSF]}
   14/7155  . . . . {for interleukins [IL]}
   14/7156  . . . . {for interferons [IFN]}
   14/7158  . . . . {for chemokines}
   14/72    . . . for hormones {(for neuromediators
   14/721   . . . . {Steroid/thyroid hormone superfamily, e.g.
GR, EcR, androgen receptor, oestrogen
   14/723   . . . . {G protein coupled receptor, e.g. TSHR-
thyrotropin-receptor, LH/hCG receptor, FSH
   14/745   . . Blood coagulation or fibrinolysis factors
   14/7455  . . . {Thrombomodulin}
   14/755   . . . Factors VIII {, e.g. factor VIII C (AHF), factor
   14/765   . . . Serum albumin, e.g. HSA
   14/775   . . Apolipopeptides
   14/78    . . Connective tissue peptides, e.g. collagen, elastin,
laminin, fibronectin, vitronectin, cold insoluble
   14/785   . . Alveolar surfactant peptides; Pulmonary
   14/79    . . Transferrins, e.g. lactoferrins, ovotransferrins
   14/795   . Porphyrin- or corrin-ring-containing peptides
   14/805   . . Haemoglobins; Myoglobins
   14/81    . Protease inhibitors
   14/8103  . . {Exopeptidase (E.C. 3.4.11-19) inhibitors}
   14/8107  . . {Endopeptidase (E.C. 3.4.21-99) inhibitors}
   14/811   . . . {Serine protease (E.C. 3.4.21) inhibitors}
   14/8114  . . . . {Kunitz type inhibitors}
   14/8117  . . . . . {Bovine/basic pancreatic trypsin inhibitor
   14/8125  . . . . . {Alpha-1-antitrypsin}
   14/8128  . . . . . {Antithrombin III}
   14/8132  . . . . . {Plasminogen activator inhibitors}
   14/8135  . . . . {Kazal type inhibitors, e.g. pancreatic
secretory inhibitor, ovomucoid}
   14/8139  . . . {Cysteine protease (E.C. 3.4.22) inhibitors, e.g.
   14/8142  . . . {Aspartate protease (E.C. 3.4.23) inhibitors,
   14/8146  . . . {Metalloprotease (E.C. 3.4.24) inhibitors, e.g.
tissue inhibitor of metallo proteinase, TIMP}
   14/815   . . from leeches, e.g. hirudin, eglin
   14/82    . Translation products from oncogenes
   16/00    Immunoglobulins [IGs], e.g. monoclonal or
polyclonal antibodies {(antibodies with enzymatic
activity, e.g. abzymes C12N 9/0002)}
1. Documents characterised by the technical
aspects of the construction of an antibody
or fragment thereof, should be classified
2. Documents not characterised by the technical
aspects of the construction of an antibody or
fragment thereof, should be classified only
according to their specificity, where necessary
accompanied by one or more appropriate indexing
   16/005   . {constructed by phage libraries}
   16/065   . . {Purification, fragmentation}
   16/08    . against material from viruses
   16/081   . . {from DNA viruses}
   16/082   . . . {Hepadnaviridae, e.g. hepatitis B virus}
   16/084   . . . {Papovaviridae, e.g. papillomavirus,
polyomavirus, SV40, BK virus, JC virus}
   16/085   . . . {Herpetoviridae, e.g. pseudorabies virus,
   16/087   . . . . {Herpes simplex virus}
   16/088   . . . . {Varicella-zoster virus, e.g.
   16/10    . . from RNA viruses {, e.g. hepatitis E virus}
   16/1009  . . . {Picornaviridae, e.g. hepatitis A virus}
   16/1018  . . . {Orthomyxoviridae, e.g. influenza virus}
   16/1027  . . . {Paramyxoviridae, e.g. respiratory syncytial
   16/1036  . . . {Retroviridae, e.g. leukemia viruses}
   16/1045  . . . . {Lentiviridae, e.g. HIV, FIV, SIV}
   16/1054  . . . . . {gag-pol, e.g. p17, p24}
   16/1063  . . . . . {env, e.g. gp41, gp110/120, gp160, V3,
   16/1072  . . . . . {Regulatory proteins, e.g. tat, rev, vpt}
   16/1081  . . . {Togaviridae, e.g. flavivirus, rubella virus, hog
   16/109   . . . . {Hepatitis C virus; Hepatitis G virus}
   16/12    . against material from bacteria
   16/1203  . . {from Gram-negative bacteria}
   16/1207  . . . {from Spirochaetales (O), e.g. Treponema,
   16/121   . . . {from Helicobacter (Campylobacter) (G)}
   16/1214  . . . {from Pseudomonadaceae (F)}
   16/1217  . . . {from Neisseriaceae (F), e.g. Acinetobacter}
   16/1221  . . . {from Brucella (G)}
   16/1225  . . . {from Bordetella (G)}
   16/1228  . . . {from Enterobacteriaceae (F), e.g. Citrobacter,
Serratia, Proteus, Providencia, Morganella,
   16/1232  . . . . {from Escherichia (G)}
   16/1235  . . . . {from Salmonella (G)}
   16/1239  . . . {from Vibrionaceae (G)}
   16/1242  . . . {from Pasteurellaceae (F), e.g. Haemophilus
   16/1246  . . . {from Rickettsiales (O)}
   16/125   . . . {from Chlamydiales (O)}
   16/1253  . . . {from Mycoplasmatales, e.g.
Pleuropneumonia-like organisms [PPLO]}
   16/1257  . . . {from Bacteridaceae (F)}
   16/126   . . . {from Legionella (G)}
   16/1264  . . . {from Rhizobiaceae (F)}
   16/1267  . . {from Gram-positive bacteria}
   16/1271  . . . {from Micrococcaceae (F), e.g.
   16/1275  . . . {from Streptococcus (G)}
   16/1278  . . . {from Bacillus (G)}
   16/1282  . . . {from Clostridium (G)}
   16/1285  . . . {from Corynebacterium (G)}
   16/1289  . . . {from Mycobacteriaceae (F)}
   16/1292  . . . {from Actinomyces; from Streptomyces (G)}
   16/1296  . . . {from Listeria}
   16/14    . against material from fungi, algea or lichens
   16/16    . against material from plants
   16/18    . against material from animals or humans
   16/22    . . against growth factors {; against growth
   16/24    . . against cytokines, lymphokines or interferons
   16/241   . . . {Tumor Necrosis Factors}
   16/242   . . . . {Lymphotoxin [LT]}
   16/243   . . . {Colony Stimulating Factors}
   16/244   . . . {Interleukins [IL]}
   16/249   . . . {Interferons}
   16/26    . . against hormones {; against hormone releasing or
   16/28    . . against receptors, cell surface antigens or cell
   16/2803  . . . {against the immunoglobulin superfamily}
   16/2806  . . . . {against CD2}
   16/2809  . . . . {against the T-cell receptor (TcR)-CD3
   16/2812  . . . . {against CD4}
   16/2815  . . . . {against CD8}
   16/2818  . . . . {against CD28 or CD152}
   16/2821  . . . . {against ICAM molecules, e.g. CD50, CD54,
   16/2824  . . . . {against CD58}
   16/2827  . . . . {against B7 molecules, e.g. CD80, CD86}
   16/283   . . . . {against Fc-receptors, e.g. CD16, CD32,
   16/2833  . . . . {against MHC-molecules, e.g. HLA-
   16/2836  . . . . {against CD106}
   16/2839  . . . {against the integrin superfamily}
   16/2842  . . . . {against integrin beta1-subunit-containing
   16/2845  . . . . {against integrin beta2-subunit-containing
   16/2848  . . . . {against integrin beta3-subunit-containing
molecules, e.g. CD41, CD51, CD61}
   16/2851  . . . {against the lectin superfamily, e.g. CD23,
   16/2854  . . . . {against selectins, e.g. CD62}
   16/2857  . . . {against nuclear receptors, e.g. retinoic acid
receptor [RAR], RXR, orphan receptor}
   16/286   . . . {against neuromediator receptors, e.g.
serotonin receptor, dopamine receptor}
   16/2863  . . . {against receptors for growth factors, growth
   16/2866  . . . {against receptors for cytokines, lymphokines,
   16/2869  . . . {against hormone receptors (for antibodies
against neuromediator receptors
   16/2872  . . . {against prion molecules, e.g. CD230}
   16/2875  . . . {against the NGF/TNF superfamily, e.g.
CD70, CD95L, CD153, CD154 (against NGF
C07K 16/22, against TNF C07K 16/241)}
   16/2878  . . . {against the NGF-receptor/TNF-receptor
superfamily, e.g. CD27, CD30, CD40, CD95}
   16/2881  . . . {against CD71}
   16/2884  . . . {against CD44}
   16/2887  . . . {against CD20}
   16/289   . . . {against CD45}
   16/2893  . . . {against CD52}
   16/2896  . . . {against molecules with a "CD"-designation,
   16/30    . . . from tumour cells
   16/3007  . . . . {Carcino-embryonic Antigens}
   16/303   . . . . {Liver or Pancreas}
   16/3038  . . . . {Kidney, bladder}
   16/3046  . . . . {Stomach, Intestines}
   16/3053  . . . . {Skin, nerves, brain}
   16/3061  . . . . {Blood cells}
   16/3069  . . . . {Reproductive system, e.g. ovaria, uterus,
   16/3076  . . . . {against structure-related tumour-associated
   16/3084  . . . . . {against tumour-associated gangliosides}
   16/3092  . . . . . {against tumour-associated mucins}
   16/32    . . against translation products of oncogenes
   16/34    . . against blood group antigens
   16/36    . . against blood coagulation factors
   16/38    . against protease inhibitors of peptide structure
   16/42    . against immunoglobulins
   16/4208  . . {against an idiotypic determinant on Ig}
   16/4216  . . . {against anti-viral Ig}
   16/4225  . . . . {against anti-HIV Ig}
   16/4233  . . . {against anti-bacterial Ig}
   16/4241  . . . {against anti-human or anti-animal Ig}
   16/425   . . . . {against anti-protozoal Ig}
   16/4258  . . . . {against anti-receptor Ig}
   16/4266  . . . . . {against anti-tumor receptor Ig}
   16/4275  . . . . . {against anti-CD4 Ig}
   16/4283  . . {against an allotypic or isotypic determinant on
   16/4291  . . . {against IgE}
   16/44    . against material not provided for elsewhere {, e.g.
haptens, metals, DNA, RNA, amino acids}
   16/46    . Hybrid immunoglobulins (hybrids of an
immunoglobulin with a peptide not being an
   16/461   . . {Igs containing Ig-regions, -domains or -residues
   16/462   . . . {Igs containing a variable region (Fv) from one
specie and a constant region (Fc) from another}
   16/464   . . . {Igs containing CDR-residues from one specie
grafted between FR-residues from another}
   16/465   . . . . {with additional modified FR-residues}
   16/467   . . . {Igs with modifications in the FR-residues
   16/468   . . {Immunoglobulins having two or more different
antigen binding sites, e.g. multifunctional
   17/00    Carrier-bound or immobilised peptides (carrier-
bound or immobilised enzymes C12N 11/00);
   17/02    . Peptides being immobilised on, or in, an organic
   17/04    . . entrapped within the carrier, e.g. gel, hollow fibre
   17/06    . . attached to the carrier via a bridging agent
   17/08    . . the carrier being a synthetic polymer
   17/10    . . the carrier being a carbohydrate
   17/12    . . . Cellulose or derivatives thereof
   17/14    . Peptides being immobilised on, or in, an inorganic
 2299/00    Coordinates from 3D structures of peptides, e.g.
 2317/00    Immunoglobulins specific features
 2317/10    . characterized by their source of isolation or
 2317/11    . . isolated from eggs
 2317/12    . . isolated from milk
 2317/13    . . isolated from plants
 2317/14    . . Specific host cells or culture conditions, e.g.
 2317/20    . characterized by taxonomic origin
 2317/21    . . from primates, e.g. man
 2317/22    . . from camelids, e.g. camel, llama or dromedary
 2317/24    . . containing regions, domains or residues from
different species, e.g. chimeric, humanized or
 2317/30    . characterized by aspects of specificity or valency
 2317/32    . . specific for a neo-epitope on a complex, e.g.
antibody-antigen or ligand-receptor
 2317/33    . . Crossreactivity, e.g. for species or epitope, or lack
 2317/34    . . Identification of a linear epitope shorter than
20 amino acid residues or of a conformational
epitope defined by amino acid residues
 2317/40    . characterized by post-translational modification
 2317/41    . . Glycosylation, sialylation, or fucosylation
 2317/50    . characterized by immunoglobulin fragments
 2317/51    . . Complete heavy chain or Fd fragment, i.e. VH +
 2317/515   . . Complete light chain, i.e. VL + CL
 2317/52    . . Constant or Fc region; Isotype
 2317/56    . . variable (Fv) region, i.e. VH and/or VL
 2317/565   . . . Complementarity determining region [CDR]
 2317/567   . . . Framework region [FR]
 2317/569   . . . Single domain, e.g. dAb, sdAb, VHH, VNAR
 2317/60    . characterized by non-natural combinations of
 2317/62    . . comprising only variable region components
 2317/622   . . . Single chain antibody (scFv)
 2317/624   . . . Disulfide-stabilized antibody (dsFv)
 2317/626   . . . Diabody or triabody
 2317/64    . . comprising a combination of variable region and
 2317/66    . . comprising a swap of domains, e.g. CH3-CH2,
 2317/70    . characterized by effect upon binding to a cell or to
 2317/71    . . Decreased effector function due to an Fc-
 2317/72    . . Increased effector function due to an Fc-
 2317/73    . . Inducing cell death, e.g. apoptosis, necrosis or
inhibition of cell proliferation
 2317/732   . . . Antibody-dependent cellular cytotoxicity
 2317/734   . . . Complement-dependent cytotoxicity [CDC]
 2317/74    . . Inducing cell proliferation
 2317/75    . . Agonist effect on antigen
 2317/76    . . Antagonist effect on antigen, e.g. neutralization or
 2317/77    . . Internalization into the cell
 2317/80    . remaining in the (producing) cell, i.e. intracellular
 2317/81    . . functional in the endoplasmatic reticulum [ER] or
 2317/82    . . functional in the cytoplasm, the inner aspect
of the cell membrane, the nucleus or the
 2317/90    . characterized by (pharmaco)kinetic aspects or by
stability of the immunoglobulin
 2317/92    . . Affinity (KD), association rate (Ka), dissociation
 2317/94    . . Stability, e.g. half-life, pH, temperature or
 2318/00    Antibody mimetics or scaffolds
 2318/10    . Immunoglobulin or domain(s) thereof as scaffolds
for inserted non-Ig peptide sequences, e.g. for
 2318/20    . Antigen-binding scaffold molecules wherein the
scaffold is not an immunoglobulin variable region
 2319/01    . containing a localisation/targetting motif
 2319/02    . . containing a signal sequence
 2319/03    . . containing a transmembrane segment
 2319/033   . . containing a motif for targeting to the internal
surface of the plasma membrane, e.g. containing a
 2319/034   . . containing a motif for targeting to the periplasmic
space of Gram negative bacteria as a soluble
protein, i.e. signal sequence should be cleaved
 2319/035   . . containing a signal for targeting to the external
surface of a cell, e.g. to the outer membrane of
Gram negative bacteria, GPI- anchored eukaryote
 2319/036   . . targeting to the medium outside of the cell, e.g.
 2319/04    . . containing an ER retention signal such as a C-
 2319/05    . . containing a GOLGI retention signal
 2319/055   . . containing a signal for localisation to secretory
 2319/06    . . containing a lysosomal/endosomal localisation
 2319/07    . . containing a mitochondrial localisation signal
 2319/08    . . containing a chloroplast localisation signal
 2319/09    . . containing a nuclear localisation signal
 2319/095   . . containing a nuclear export signal
 2319/10    . . containing a tag for extracellular membrane
 2319/20    . containing a tag with affinity for a non-protein
 2319/21    . . containing a His-tag
 2319/22    . . containing a Strep-tag
 2319/23    . . containing a GST-tag
 2319/24    . . containing a MBP (maltose binding protein)-tag
 2319/30    . Non-immunoglobulin-derived peptide or protein
having an immunoglobulin constant or Fc region, or
a fragment thereof, attached thereto
 2319/31    . fusions, other than Fc, for prolonged plasma life,
 2319/32    . fusions with soluble part of a cell surface receptor,
 2319/33    . fusions for targeting to specific cell types, e.g. tissue
specific targeting, targeting of a bacterial subspecies
 2319/35    . containing a fusion for enhanced stability/folding
during expression, e.g. fusions with chaperones or
 2319/40    . containing a tag for immunodetection, or an epitope
 2319/41    . . containing a Myc-tag
 2319/42    . . containing a HA(hemagglutinin)-tag
 2319/43    . . containing a FLAG-tag
 2319/50    . containing protease site
 2319/55    . containing a fusion with a toxin, e.g. diphteria toxin
 2319/60    . containing spectroscopic/fluorescent detection, e.g.
green fluorescent protein [GFP]
 2319/61    . containing an enzyme fusion for detection (lacZ,
 2319/70    . containing domain for protein-protein interaction
 2319/705   . . containing a protein-A fusion
 2319/71    . . containing domain for transcriptional activaation,
 2319/715   . . . containing a domain for ligand dependent
transcriptional activation, e.g. containing a
 2319/72    . . containing SH2 domain
 2319/73    . . containing coiled-coiled motif (leucine zippers)
 2319/735   . . containing a domain for self-assembly, e.g. a viral
coat protein (includes phage display)
 2319/74    . . containing a fusion for binding to a cell surface
 2319/75    . . . containing a fusion for activation of a cell
surface receptor, e.g. thrombopoeitin, NPY and
 2319/80    . containing a DNA binding domain, e.g. Lacl or Tet-
 2319/81    . . containing a Zn-finger domain for DNA binding
 2319/85    . containing an RNA binding domain
 2319/90    . containing a motif for post-translational
 2319/91    . . containing a motif for glycosylation
 2319/912   . . . containing a GPI (phosphatidyl-inositol
 2319/915   . . containing a motif for acylation
 2319/92    . . containing an intein ("protein splicing")domain
 2319/95    . containing a motif/fusion for degradation (ubiquitin